PathAI is a leading provider of AI-powered research tools and services for pathology.
PathAI is evolving pathology using machine learning and deep learning techniques to drive faster more accurate diagnosis of disease.
PathAI was founded in 2016 by Andrew H. Beck & Aditya Khosla. The company is headquartered in Boston, Massachusetts.
PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
PathAI's deep-learning solutions drive discovery and predictive diagnostics in drug-development. PathAI's technology accelerates R&D efforts and brings standardization to all phases of the drug development pipeline.
PathAI is backed by D1 Capital Partners, General Atlantic, General Catalyst, Kaiser Permanente, Bristol-Myers Squibb, Merck, LabCorp and others. The company raised $165M in Series C round on May 18, 2021. This brings PathAI's total funding to $255.2M to date.